AOP Orphan Pharmaceuticals Aktiengesellschaft
Contact:
Olena Weissenbacher
Phone: +43 503 72 44-24
E-Mail: olena.weissenbacher@aoporphan.com
Contact:
Olena Weissenbacher
Phone: +43 503 72 44-24
E-Mail: olena.weissenbacher@aoporphan.com
KEYWORDS:
- CNS & Gastroenterology
- Cardiology & Pulmonology
- Hematology & Oncology
- AOP Orphan Pharmaceuticals AG
- Dr. Georg Fischer
- Landiolol
- Rapibloc
- Beta Blocker Rapibloc
- AOP ORPHAN
attachments to announcement
AOP Orphan announces European approvable opinion of its ultra-short acting beta blocker Rapibloc®
back to announcementPDFs
 [ download PDF ] | title: AOP Orphan - beta blocker Rapibloc® image text: AOP Orphan Pharmaceuticals AG announces European "approvable" opinion of its ultra-short acting beta blocker Rapibloc® (Landiolol). copyright: AOP Orphan Pharmaceuticals AG |
